

Chapter 235

Antiangiogenic Agents

Ricardo L. Berrios, Michael Y. Bonner,
Jonathan Hofmekler, & Jack L. Arbiser

REFERENCES

1. Folkman J: Tumor angiogenesis: Therapeutic implications. *N Engl J Med* **285**:1182,1971
2. Folkman J: Angiogenesis. *Annu Rev Med* **57**:1, 2006
3. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. *Nat Rev Cancer* **2**:727,2002
4. <http://www.drugs.com/ppa/interferon-alfa-2b.html>, accessed 2010.
5. Michaud AP et al: Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. *Laryngoscope* **114**:1231-1236, 2004
6. Tagliaferri P et al: New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. *Cancer Immunol Immunother* **54**:1, 2005
7. Arbiser JL: Antiangiogenic therapy and dermatology: A review. *Drugs of Today* **33**:687, 1997
8. Jain RK et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* **3**:24, 2006
9. <http://www.drugs.com/ppa/bevacizumab.html>, accessed 2010
10. Million RP: Therapeutic area crossroads: Anti-angiogenesis. *Nature Reviews Drug Discovery* **7**:115-116, 2008
11. <http://www.drugs.com/ppa/ranibizumab.html>, accessed 2010.
12. Ferrara N et al: The vascular endothelial growth factor family of polypeptides. *J Cell Biochem* **47**:211-218, 1991
13. <http://www.drugs.com/ppa/pegaptanib-sodium.html>, accessed 2010
14. Vincenzi B et al: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. *Ann Oncol* **17**:835-841, 2006
15. Perrotte P et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. *Clin Cancer Res* **5**:257-265, 1999
16. <http://www.drugs.com/ppa/cetuximab.html>, accessed 2010
17. Cohenuram M, Saif MW: Panitumumab the first fully human monoclonal antibody from the bench to the clinic. *Anticancer Drugs* **18**:7-15, 2007
18. <http://www.drugs.com/ppa/panitumumab.html>, accessed 2010
19. Izumi Y et al: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. *Nature* **416**:279-280, 2002
20. <http://www.drugs.com/ppa/trastuzumab.html>, accessed 2010
21. Nguyen A et al: Angiogenesis in cutaneous disease: Part I. *J Am Acad Dermatol* **61**(6):921-942, 2009
22. <http://www.drugs.com/ppa/sunitinib-malate.html>, accessed 2010
23. Nguyen S, Franklin M, Dudek AZ: Skin ulcers in Klippel—Trenaunay syndrome respond to sunitinib. *Transl Res* **151**:194-196, 2008
24. Ng R, Chen EX: Sorafenib (BAY 43–9006): A review of clinical development. *Curr Clin Pharmacol* **1**:223-228, 2006
25. Plaza-Menacho I et al: Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. *J Biol Chem* **282**:29230-29240, 2007
26. <http://www.drugs.com/ppa/sorafenib.html>, accessed 2010
27. <http://www.drugs.com/ppa/erlotinib.html>, accessed 2010
28. Bartlett JB et al: Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. *Br J Cancer* **93**:613, 2005
29. LiX et al: Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. *Anticancer Res* **23**:2481-2487, 2003

30. Rosenbach M, Werth VP: Dermatologic therapeutics: Thalidomide. A practical guide. *Dermatol Ther* **20**: 175–186, 2007
31. D'Amato RJ et al: Thalidomide is an inhibitor of angiogenesis. *USASA Proc Natl Acad Sci* **91**:4082, 1994
32. Fuchida SI et al: The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. *Int J Lab Hematol* **30**(3):220-229, 2008
33. Nasca MR et al: Thalidomide increases human keratinocyte migration and proliferation. *J Invest Dermatol* **113**(5):720-724, Nov, 1999
34. <http://www.drugs.com/ppa/thalidomide.html>, accessed 2010
35. Stephens TD, Bunde CJ, Fillmore BJ: Mechanism of action in thalidomide teratogenesis. *Biochem Pharmacol* **59**(12):1489-1499, 2000
36. Faver IR et al: Thalidomide for dermatology: A review of clinical uses and adverse effects. *Int J Dermatol* **44**: 61, 2005
37. Testerman TL et al: Cytokine induction by the immunomodulators imiquimod and S-27609. *J Leukoc Biol* **58**:365-372, 1995
38. Majewski S et al: Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. *Int J Dermatol* **44**:14-9, 2005
39. Hesling C et al: In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. *Br J Dermatol* **150**:761-767, 2004
40. Miller RL et al: Imiquimod applied topically: A novel immune response modifier and new class of drug. *Int J Immunopharmacol* **21**:1-14, 1999
41. Suzuki H et al: Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. *J Invest Dermatol* **114**:135-141, 2000
42. <http://www.drugs.com/pro/imiquimod.html>, accessed 2010
43. Ezzell TI, Fromowitz JS, Ramos-Caro FA: Recurrent pyogenic granuloma treated with topical imiquimod. *J Am Acad Dermatol* **54**:244, 2006
44. Li VW et al: Imiquimod as an antiangiogenic agent. *J Drugs Dermatol* **4**:708, 2005
45. Sidbury R et al: Topically applied imiquimod inhibits vascular tumor growth in vivo. *J Invest Dermatol* **121**:1205, 2003
46. Gul U et al: A case of generalized discoid lupus erythematosus: successful treatment with imiquimod cream 5%. *Adv Ther* **23**:787-792, 2006
47. Chang CJ et al: Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks. *Lasers Surg Med* **40**:605-610, 2008
48. Tremaine AM et al: Combined therapy for enhanced microvascular destruction in port wine stains: pulsed dye laser photo-thermolysis and imiquimod. Presented at: Annual Meeting of the American Society for Laser Medicine and Surgery. Washington D.C., 2009.
49. Rao RD, Buckner JC, Sarkaria JN: Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. *Curr Cancer Drug Targets* **4**:621, 2004
50. Kwon YS, Kim JC: Inhibition of corneal neovascularization by rapamycin. *Exp Mol Med* **38**:173, 2006.
51. Sarbassov DD et al: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. *Mol Cell* **22**:159-168, 2006
52. <http://www.drugs.com/ppa/sirolimus.html>, accessed 2010
53. Chumsri S et al: Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. *Leuk Lymphoma* **49**:359-361, 2008
54. Zhang Q et al: Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome. *USASA Proc Natl Acad Sci* **93**:9148-9153, 1996
55. Saggat S et al: Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. *Arch Dermatol* **144**:654-657, 2008
56. Hofbauer GF et al: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. *Br J Dermatol* **159**:473-475, 2008
57. Reitamo S et al: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial. *Br J Dermatol* **145**:438-445, 2001
58. Swaminathan S et al: Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: Possible role of phospho-70-ribosomal-S6 kinase. *J Am Acad Dermatol* **62**(2):343-345, 2010
59. Fried L et al: Efficacy of rapamycin in scleroderma: A case study. *Lymphat Res Biol* **6**(3-4):217-219, 2008

60. Nadiminti U, Arbiser JL: Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. *J Am Acad Dermatol* **52**(2 Suppl. 1):17-19, 2005
61. Warino L, Libecco J: Cutaneous effects of sirolimus in renal transplant recipients. *J Drugs Dermatol* **5**:273, 2006
62. <http://www.drugs.com/ppa/temsirolimus.html>, accessed 2010
63. Bianco R et al: Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. *Br J Cancer* **98**:923-930, 2008
64. Cejka D et al: Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. *Cancer Biol Ther* **7**:1377-1385, 2008
65. <http://www.drugs.com/ppa/everolimus.html>, accessed 2010
66. Frigerio E et al: Severe psoriasis treated with a new macrolide: everolimus. *Br J Dermatol* **156**:372-374, 2007
67. Ludwig H et al: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. *Cancer* **104**:1794, 2005
68. Roccaro AM et al: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. *Cancer Res* **66**:184, 2006
69. Zinzani PL et al: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. *J Clin Oncol* **25**:4293-4297, 2007
70. <http://www.drugs.com/ppa/bortezomib.html>, accessed 2010
71. El Filali M et al: Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. *Mol Vis* **14**:1752-1759, 2008
72. Wilson C et al: Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. *Br J Cancer* **99**:2054-2064, 2008
73. Sung J et al: Sequential delivery of dexamethasone and VEGF to control local tissue response for carbon nanotube fluorescence based micro-capillary implantable sensors. *Biomaterials* **30**:622-631, 2009
74. Goldman R: Growth factors and chronic wound healing: Past, present, and future. *Adv Skin Wound Care* **17**:24, 2004
75. <http://www.drugs.com/ppa/becaplermin.html>, accessed 2010
76. Cohen MA, Eaglstein WH: Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. *J Am Acad Dermatol* **45**:857-862, 2001
77. Metz BJ et al: Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. *Arch Dermatol* **140**:867-870, 2004
78. Metz BJ, Rubenstein MC, Levy ML, Metry DW: Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. *Arch Dermatol* **140**:867-870, 2004
79. Hoekstra R et al: Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1—mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. *J Clin Oncol* **23**:5188-5197, 2005
80. Markovic SN et al: A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. *Am J Clin Oncol* **30**:303-309, 2007
81. Bai X et al: Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. *J Biol Chem* **278**:35501, 2003
82. Perry BN et al: Pharmacologic blockade of angio-pietin-2 is efficacious against model hemangiomas in mice. *J Invest Dermatol* **126**(10):2316-2322, 2006
83. Lapidoth M et al: Efficacy of topical application of eosin for ulcerated hemangiomas. *J Am Acad Dermatol* **60**(2):350-351, 2001
84. Bhandarkar SS et al: Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. *J Clin Invest* **119**(8):2359-2365, 2009
85. Arbiser JL et al: Curcumin is an in vivo inhibitor of angiogenesis. *Mol Med* **4**:376, 1998
86. Sharma RA, Gescher AJ, Steward WP: Curcumin: The story so far. *Eur J Cancer* **41**:1955, 2005
87. Arbiser JL et al: Altered basic fibroblast growth factor expression in common epidermal neoplasms: Examination with in situ hybridization and immunohistochemistry. *J Am Acad Dermatol* **42**:973, 2000
88. Yao L et al: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. *Blood* **93**:1612, 1999

